Weathering the Storm: Products Divide the Successes Among the Biotech IPO Class of 2000
This article was originally published in Start Up
Executive Summary
Despite the market rise in the 2nd quarter of 2003, investor skepticism about biotech's IPO class of 2000 remains high--especially for those with no products in Phase III trials.